Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

31°
- Benton, AR (72018)
  Today
  
  Abundant sunshine. High around 60F. Winds light and variable..
  
  Tonight
  
  Clear skies. Low 36F. Winds light and variable.
  
  Updated: December 31, 2025 @ 8:02 am
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

19.44 +0.24 (+1.25%)

Streaming Delayed Price Updated: 9:57 AM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYN

June 23, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

June 20, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

June 18, 2025

From Pomerantz LLP

Via GlobeNewswire

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks ↗

March 12, 2025

On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Via Benzinga

Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial ↗

June 17, 2025

The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes.

Via Stocktwits

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

June 17, 2025

From The DJS Law Group

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 17, 2025

Via Benzinga

Which stocks are moving on Tuesday? ↗

June 17, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? ↗

June 17, 2025

Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating DM1.

Via Benzinga

Get insights into the top gainers and losers of Tuesday's pre-market session. ↗

June 17, 2025

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 17, 2025

Via Benzinga

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

June 17, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 16, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

June 16, 2025

Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

June 16, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

June 05, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 08, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

April 24, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

April 15, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 14, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

April 11, 2025

Via Benzinga

JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path ↗

March 21, 2025

JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.

Via Benzinga

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

March 20, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

March 20, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

March 16, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

March 11, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

February 27, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

February 14, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 03, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

All News about Dyne Therapeutics, Inc. - Common Stock

Sections

Services

Follow Us